FDA Approves Schizophrenia Drug Abilify
Posted on: Thursday, 8 November 2007, 12:00 CST
Otsuka Pharmaceutical and Bristol-Myers Squibb have announced that the FDA has approved the drug Abilify for the treatment of schizophrenia in adolescents aged 13-17 years.
This approval is based on results from a six-week, randomized, double- blind, placebo-controlled study that demonstrated significant improvement with Abilify compared to placebo on the primary efficacy endpoint, positive and negative syndrome scale (PANSS) total score.
Tatsuo Higuchi, president and representative director at Otsuka Pharmaceutical, said: "We are extremely pleased that Abilify, the first available dopamine partial agonist, is approved for the treatment of pediatric patients (13 to 17 years of age) suffering from schizophrenia. Abilify offers an effective new option to help treat this serious mental illness."
Elliott Sigal, executive vice president, chief scientific officer and president of R&D at Bristol-Myers Squibb, said: "Schizophrenia is one of the most complex of all mental health disorders. We remain committed to providing innovative therapies, such as Abilify, to help patients, including adolescents, living with schizophrenia."
Source: Datamonitor
Related Articles
- Abilify Has Made Strong Gains in Patient Share Across All Lines of Therapy Since Last Year's Analysis of Prescribing Trends in Schizophrenia
- U.S. Food and Drug Administration Approves ABILIFY(R) (Aripiprazole) for Adolescent Patients With Schizophrenia
- ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
- BMS, Otsuka Launch Fast-Dissolve Abilify
- Drug to Treat Schizophrenia With a New Mechanism of Action, Antipsychotic Agent ''Abilify(R)'' Available in Japan From June 8
- Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. Announce Availability of 2 Mg ABILIFY(R) (Aripiprazole) Tablet and Nonrefrigerated Oral Solution
- Abilify plus an antidepressant for mood disorders
- Association Between the Neuregulin 1 Gene and Schizophrenia: A Systematic Review
- Pharmacological Treatments for First-Episode Schizophrenia
 |
 |
User Comments (0)
RSS Feeds